Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2021 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update

- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA -...
June 11, 2021 08:00 ET | Source: BeyondSpring, Inc.

BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
June 10, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting

- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as chemotherapy), had...
June 08, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting

NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
June 07, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting

- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better...
June 04, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces First Patient Dosed in a Triple Combination Study with Plinabulin, PD-1/PD-L1 Inhibitor and Radiotherapy for the Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapyFirst patient who failed Keytruda and chemotherapy...
June 01, 2021 07:00 ET | Source: BeyondSpring, Inc.

BeyondSpring Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Plinabulin and G-CSF Combination for the Prevention of Chemotherapy-Induced Neutropenia (CIN)

- The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date for November 30, 2021 - Plinabulin and G-CSF combination has the potential to raise the standard of care in CIN...
May 26, 2021 16:05 ET | Source: BeyondSpring, Inc.

BeyondSpring to Present at the Jefferies Virtual Healthcare Conference on June 3, 2021

NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
May 24, 2021 07:30 ET | Source: BeyondSpring, Inc.

BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual Meeting

- Data from U.S. Phase 1 dose escalation investigator-initiated trial demonstrated favorable safety and tolerability. - Plinabulin, in combination with nivolumab and ipilimumab, shows 46% objective...
May 10, 2021 08:18 ET | Source: BeyondSpring, Inc.

BeyondSpring to Present at the Bank of America Securities 2021 Health Care Conference on May 13, 2021

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...